AUTHORS
Annalisa Paviglianiti, MD, PhD, Chiara Giacon2, Linda Koster3, Joanna Drozd-Sokolowska4, Kavita Raj5, Inas El-Najjar6, Laurent Garderet7, Meral Beksac, MD8, Christof Scheid, MD9, Nicola Polverelli, MD10, Marie Robin, MD11, Patrick J. Hayden12, Donal McLornan13
AFFILIATIONS
1 Hospital de la Santa Creu i Sant Pau, IR Sant Pau and José Carreras Leukemia Research Institutes, Universitat Autónoma de Barcelona, Barcelona, Spain
2 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3 EBMT Study unit, Leiden, Netherlands
4 University Clinical Centre, Medical University of Warsaw, Warsaw, Poland
5 University College London Hospitals NHS Trust, London, United Kingdom
6 Abu Dhabi Stem Cell Center, Abu Dhabi, United Arab Emirates
7 Hôpital Pitié Salpêtrière, Paris, France
8 Istinye University Ankara Liv Hospital, Ankara, Turkey
9 University of Cologne, Cologne, Germany
10 Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
11 Hopital Saint Louis, Paris, France
12 Trinity College Dublin, St. James’s Hospital, Dublin, Ireland
13 University College London Hospitals NHS Trust, London, United Kingdom
ABSTRACT
Background: Outpatient autologous hematopoietic cell transplantation (auto-HCT) is an increasingly feasible procedure for patients with multiple myeloma (MM). Different models have been developed over the years. However, the extent of implementation and the clinical organization of the outpatient model across the EBMT network is poorly characterized.
Methods: we conducted a survey on behalf of the Chronic Malignancies Working Party of the EBMT exploring the use of outpatient auto-HCT. Between April and June 2026, a 41-item electronic questionnaire was distributed to 137 EBMT centers that had performed at least 25 auto-HCT for MM over the previous five years, with three follow-up reminders. Responses were analyzed via descriptive statistics.
Results: Responses were received from 56 centres in 20 countries, giving an overall response rate of 40.9%. Of these, 47 (83.9%) were classified as academic centers. Twenty-three centers reported >50 auto-HCT in 2024. A total of 19/56 centers (33.9%) were performing outpatient auto-HCT. Among 37 centers without an outpatient program, 3 (8.3%) were planning implementation while 21 (58.3%) were not (1 missing). Among the 19 centers with established outpatient programs, 8 (44.4%) had been operating for <5 years, 7 (38.9%) for 5-10 years, and 3 (16.7%) for >10 years (1 missing). The most common model was total outpatient care (8 centres; 42.1%); the next most common was early discharge (7; 36.8%). Delayed admission and at-home models were each employed by two centres (10.5% each), respectively. Outpatient central venous catheter insertion was performed in 13/19 (68.4%) and as an inpatient in 6/19 (31.6%); administration of high-dose melphalan and the stem-cell infusion were each administered without overnight admission in 9/19 (47.4%) and as an inpatient in 10/19 (52.6%). Management of the aplastic phase consisted of regular day-unit attendance in 13/18 (72.2%), hospital review only when clinically indicated with daily nursing review in 4/18 (22.2%), and home medical review in 1/18 (5.6%) (1 missing information).
Criteria for patient selection included performance status (18/19, 94.7%), distance from hospital (17/19, 89.5%), patient preference (16/19, 84.2%), and availability of a 24-hour caregiver (15/19, 78.9%); age as a discriminator was used by 4/19 (21.1%). Common exclusion criteria were >1 hour distance from hospital (17/19, 89.5%), ECOG >2 (16/19, 84.2%), no caregiver (14/19, 73.7%), and psychiatric disease (13/19, 68.4%).
Patients were most frequently discharged from the hospital to the outpatient program at day 0 (7/19; 36.8%). In 5/19 (26.3%) they were never admitted (total outpatient program). G-CSF was used by 13/19 (68.4%), most frequently from Day+7 (6/13; 46.1%). Corticosteroid prophylaxis for engraftment syndrome was administered in 3/19 (15.8%) from Day+5. Prophylaxis with acyclovir and fluoroquinolones was used by 16/19 (84.2%) centers, and azoles by 13/19 (68.4%). Home monitoring involved in-person HCT-trained nurses in 8/13 (61.5%), in-person hematologists in 7/13 (53.8%), remote nursing in 4/13 (30.8%), and remote physician review in 3/13 (23.1%). None of the centers reported administering red blood cell transfusions at home. Complications attributed to home-based care were reported by 10/16 (62.5%); all of which resulted in emergency readmission. Fever was selected as a readmission indication by 19/19 (100%) centers and severe oral mucositis or gastrointestinal toxicity by 16/19 (84.2%). No center reported higher infection rates than seen with inpatient care; 11/19 (57.9%) reported similar and 7/19 (36.8%) lower rates. Patient satisfaction was formally assessed in 11/19 (57.9%), whereas caregiver burden was evaluated in only 4/19 (21.1%). Full reimbursement was available in 9/19 (47.4%) and partial reimbursement in 3/19 (15.8%). Key barriers to home-based care were logistics (13/18, 72.2%), patient/caregiver resistance (8/18, 44.4%), staffing (6/18, 33.3%), and reimbursement (4/18, 22.2%).
Conclusions: Outpatient auto-HCT for MM remains a relatively poorly developed practice across responding EBMT centers, having been implemented in only one-third of responding centers. There is marked heterogeneity in treatment settings, supportive care, home monitoring, and reimbursement. These data support EBMT-led efforts to harmonize eligibility and readmission criteria, as well as the development of guidelines to facilitate the broader adoption of this treatment modality
DISCLOSURES
Annalisa Paviglianiti, MD, PhD: No relevant conflicts of interest to declare.